Why the study?
Do CYP2C9 gene variants affect the required dose of warfarin and the incidence of bleeding complications in patients starting anticoagulation?
Population
180 patients starting anticoagulation with warfarin, followed up at one specialized clinic
Comparison
Presence of CYP2C9*2 and/or CYP2C9*3 haplotypes vs Presence of CYP2C9*1 haplotype
Design
Cohort
Loading...
May warrant bleeding risk awareness in CYP2C9 variant carriers; leaves open whether genotyping improves warfarin outcomes.
Do CYP2C9 gene variants affect the required dose of warfarin and the incidence of bleeding complications in patients starting anticoagulation?
CYP2C9 gene variants significantly modulate the required warfarin dose and increase the risk of bleeding complications, particularly in the presence of local bleeding sources.
A 2000 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: